Immune-Mediated Thrombocytopenia (ITP)

Immune-mediated thrombocytopenia (ITP) is a serious autoimmune disorder in horses characterized by the immune system's inappropriate destruction of the body's own platelets, the cellular components essential for proper blood clotting. In this condition, the horse's immune system produces antibodies that target and destroy platelets, leading to dangerously low platelet counts known as thrombocytopenia. This destruction occurs primarily in the spleen, liver, and bone marrow, where antibody-coated platelets are recognized as foreign and eliminated by macrophages. The resulting deficiency in circulating platelets compromises the horse's ability to form blood clots, leading to spontaneous bleeding and hemorrhage that can range from minor bruising to life-threatening internal bleeding.

Immune-mediated thrombocytopenia can affect horses of any age, breed, or gender, though it is most commonly diagnosed in adult horses between four and fifteen years of age. The condition may occur as a primary disorder with no identifiable underlying cause, termed idiopathic ITP, or as a secondary condition triggered by infections, medications, vaccinations, neoplasia, or other immune-mediated diseases. Primary ITP accounts for approximately half of diagnosed cases, while secondary ITP requires identification and treatment of the underlying trigger in addition to managing the platelet deficiency. The condition appears sporadically throughout equine populations without strong geographic or seasonal patterns.

The impact of ITP on equine health can be profound and potentially life-threatening if not promptly recognized and treated. Horses with severely depleted platelet counts are at significant risk for spontaneous hemorrhage into vital organs, muscles, and body cavities, as well as excessive bleeding from minor wounds or routine procedures. The condition can progress rapidly from subtle signs like small hemorrhages in the gums or under the skin to severe bleeding episodes that may prove fatal without aggressive intervention. Performance horses may experience career-limiting complications, while even recreational horses face serious health consequences without appropriate treatment.

Fortunately, immune-mediated thrombocytopenia is treatable in most cases when diagnosed early and managed appropriately with immunosuppressive medications. Early detection through recognition of bleeding symptoms and confirmation via blood testing allows for prompt initiation of treatment, which typically results in platelet count recovery within days to weeks. However, the condition requires careful monitoring during treatment, and some horses may experience relapses requiring repeat therapy or long-term immunosuppressive management. Understanding the signs of ITP and seeking immediate veterinary attention at the first indication of abnormal bleeding is critical for achieving the best possible outcomes.

The primary cause of immune-mediated thrombocytopenia is a malfunction of the immune system in which the body produces antibodies that incorrectly identify platelets as foreign invaders requiring destruction. These autoantibodies, typically of the immunoglobulin G (IgG) class, bind to surface proteins on platelets, marking them for removal by the reticuloendothelial system. Once coated with antibodies, platelets are recognized by macrophages in the spleen and liver, which engulf and destroy them at a rate far exceeding the bone marrow's ability to produce replacement platelets. This accelerated destruction results in the severely depleted platelet counts characteristic of ITP, with normal equine platelet counts of 100,000-300,000 per microliter potentially dropping to fewer than 10,000 per microliter in severe cases.

While genetic predisposition to autoimmune diseases has not been extensively studied in horses, certain familial patterns suggest that hereditary factors may influence susceptibility to immune-mediated conditions including ITP. Horses with family histories of autoimmune disorders may carry genetic variations affecting immune system regulation, potentially predisposing them to inappropriate immune responses against self-tissues. Additionally, certain breed lines may demonstrate higher incidences of autoimmune conditions, though specific genetic markers for ITP susceptibility in horses have not been definitively identified. Research in other species suggests that major histocompatibility complex variations and immune regulatory gene polymorphisms may influence autoimmune disease development.

Environmental and management factors can serve as triggers for secondary immune-mediated thrombocytopenia in susceptible horses. Viral and bacterial infections are among the most common triggers, with the immune response generated against infectious agents occasionally cross-reacting with platelet surface proteins through a process called molecular mimicry. Equine infectious anemia, equine herpesvirus, and streptococcal infections have all been associated with secondary ITP development. Certain medications, including some antibiotics and non-steroidal anti-inflammatory drugs, may trigger immune-mediated platelet destruction in individual horses through drug-induced antibody formation.

Risk factors for developing ITP include recent illness, vaccination, surgery, or other events that stimulate significant immune system activation. Middle-aged horses appear most commonly affected, possibly due to accumulated immune system dysregulation over time. Horses with concurrent immune-mediated conditions such as autoimmune hemolytic anemia or systemic lupus erythematosus are at elevated risk for developing ITP as part of a broader autoimmune syndrome. Stress, whether from transportation, competition, herd changes, or illness, may contribute to immune system dysregulation and trigger episodes in susceptible individuals.

The pathophysiology of ITP involves complex interactions between the adaptive immune system, platelets, and the organs responsible for blood cell clearance and production. Autoantibody production begins when B lymphocytes incorrectly recognize platelet surface glycoproteins as foreign antigens and initiate an immune response. The resulting antibodies bind to circulating platelets, facilitating their recognition and phagocytosis by macrophages in the spleen and liver. The bone marrow typically attempts to compensate by increasing platelet production, but when destruction rates exceed production capacity, thrombocytopenia develops. In some cases, autoantibodies may also target megakaryocytes, the bone marrow cells responsible for platelet production, further impairing the body's compensatory response.

Early warning signs of immune-mediated thrombocytopenia in horses are often subtle and easily overlooked, particularly since horses instinctively hide signs of illness as prey animals. Initial symptoms may include small red or purple spots on the gums, inner surfaces of the lips, or underneath the tongue, representing petechial hemorrhages caused by capillary bleeding into tissues. Owners may notice occasional blood-tinged mucus from the nostrils without any history of trauma, or observe that minor scrapes and wounds bleed longer than expected before clotting. Some horses may appear slightly more subdued than usual or show mild reluctance to exercise, though these nonspecific signs are frequently attributed to other causes or dismissed entirely.

Common symptoms of ITP as the condition progresses include increasingly visible hemorrhages throughout the body's mucous membranes and skin. Petechiae may coalesce into larger areas of hemorrhage called ecchymoses, appearing as purple bruise-like patches on the gums, sclera of the eyes, vulvar or penile mucosa, and unpigmented skin. Spontaneous nosebleeds may become more frequent and prolonged, and blood may appear in the urine or feces without any underlying gastrointestinal or urinary tract pathology. Horses may develop visible swellings from hemorrhage into muscles or subcutaneous tissues, particularly over bony prominences or areas subject to minor trauma.

Behavioral changes associated with ITP often reflect the horse's response to internal discomfort and weakness from blood loss. Affected horses may become depressed and show decreased interest in food, water, and their surroundings. They may stand with heads lowered, move stiffly due to muscle hemorrhage pain, or become reluctant to lie down and rise normally. Some horses display mild colic-like behaviors including pawing, looking at their flanks, or assuming stretched postures, particularly if bleeding occurs within the abdominal cavity. Social dynamics may shift as affected horses withdraw from herd interactions or allow themselves to be displaced from food and water sources.

Physical signs visible on examination include pale mucous membranes reflecting blood loss, prolonged capillary refill time, and elevated heart and respiratory rates as the cardiovascular system compensates for reduced oxygen-carrying capacity. Body temperature may be normal or slightly elevated if inflammation accompanies the immune process. Careful examination often reveals petechiae and ecchymoses in locations not immediately visible, including inside the ears, on the prepuce or vulva, and beneath the tail. Auscultation may reveal increased gut sounds from gastrointestinal irritation by blood, or abnormal heart sounds if pericardial hemorrhage has occurred.

Symptom progression in untreated ITP follows a concerning trajectory as platelet counts continue to decline. Hemorrhages become more extensive and spontaneous, with bleeding occurring into joints causing lameness, into the respiratory tract causing coughing and labored breathing, and into the gastrointestinal tract causing dark, tarry feces or frank blood in the stool. Some horses develop significant internal hemorrhage into body cavities, with abdominal distension from hemoperitoneum or respiratory compromise from hemothorax. Progressive anemia develops as blood loss exceeds the body's ability to regenerate red blood cells, compounding the effects of the platelet deficiency.

Emergency symptoms requiring immediate veterinary attention include severe or uncontrolled bleeding from any site, signs of shock such as cold extremities and extreme weakness, labored breathing suggesting pulmonary or pleural hemorrhage, and acute severe colic potentially indicating intra-abdominal bleeding. Horses showing sudden collapse, severe depression, or rapidly worsening condition despite previous stability require emergency evaluation. Bleeding from injection sites, wounds, or following routine procedures like dental floating or hoof trimming that cannot be controlled with normal measures indicates critical platelet deficiency requiring urgent intervention.

Physical examination of horses suspected of having immune-mediated thrombocytopenia begins with a thorough evaluation of all visible mucous membranes for evidence of petechial or ecchymotic hemorrhages. The veterinarian carefully examines the gums, tongue, sclera, nasal passages, vulva or prepuce, and any unpigmented skin for signs of spontaneous bleeding. Vital parameters including heart rate, respiratory rate, temperature, and capillary refill time are assessed to evaluate cardiovascular status and detect signs of blood loss. The entire body is palpated for swellings, masses, or painful areas that might indicate hemorrhage into muscles or body cavities. A complete history is obtained regarding recent illnesses, vaccinations, medications, and any observed bleeding episodes.

Diagnostic testing for ITP centers on the complete blood count (CBC), which reveals the characteristic severe thrombocytopenia with platelet counts often below 20,000 per microliter. The CBC also evaluates red blood cell parameters to assess concurrent anemia from blood loss and white blood cell counts to help rule out infectious causes. Examination of a blood smear by the laboratory confirms the low platelet count and evaluates platelet size, as increased platelet size suggests active bone marrow response. Coagulation panels including prothrombin time and activated partial thromboplastin time are typically normal in ITP, as these pathways remain intact, helping distinguish the condition from other bleeding disorders. Serum biochemistry panels assess organ function and may reveal evidence of internal hemorrhage.

Advanced diagnostics may be necessary to confirm the immune-mediated nature of the disease and rule out underlying causes. Bone marrow aspiration and evaluation can demonstrate increased megakaryocyte numbers, confirming that the marrow is appropriately attempting to increase platelet production in response to peripheral destruction. Antiplatelet antibody testing, though not widely available, can directly demonstrate the presence of antibodies coating platelets. Ultrasound examination of the abdomen may reveal evidence of internal hemorrhage, splenic enlargement, or underlying neoplasia. Testing for specific infectious diseases including equine infectious anemia, ehrlichiosis, and equine herpesvirus helps identify potential secondary causes requiring specific treatment.

Differential diagnosis for thrombocytopenia in horses includes several conditions that must be distinguished from primary ITP. Disseminated intravascular coagulation (DIC) causes platelet consumption and produces abnormal coagulation parameters alongside the low platelet count. Bone marrow suppression from toxins, infections, or neoplasia reduces platelet production and may affect other blood cell lines. Severe sepsis and endotoxemia can cause thrombocytopenia through various mechanisms including platelet consumption and sequestration. Drug-induced thrombocytopenia requires identification of the offending medication for definitive diagnosis. Splenic sequestration, massive hemorrhage, and pseudothrombocytopenia from blood sampling artifacts must also be considered and ruled out through appropriate testing.

Emergency treatment of immune-mediated thrombocytopenia focuses on stabilizing horses with severe bleeding and initiating immunosuppressive therapy to halt platelet destruction. Horses presenting with active hemorrhage or signs of significant blood loss require immediate supportive care including intravenous fluid therapy to maintain blood pressure and tissue perfusion. Blood transfusions may be necessary for horses with severe anemia, though transfused platelets are typically destroyed rapidly by circulating autoantibodies and provide only temporary benefit. Strict stall rest is instituted to minimize trauma risk, and all unnecessary procedures including blood sampling are avoided until platelet counts improve. Pressure bandaging and topical hemostatic agents are applied to any visible bleeding sites.

Medical management of ITP relies primarily on immunosuppressive medications to reduce autoantibody production and platelet destruction. Corticosteroids, particularly dexamethasone administered intravenously or intramuscularly at immunosuppressive doses, represent the first-line treatment and typically produce rapid improvement in platelet counts within three to seven days. Prednisolone may be used for longer-term oral maintenance therapy once initial control is achieved. For refractory cases not responding adequately to corticosteroids alone, additional immunosuppressive agents such as azathioprine or mycophenolate may be added to the treatment protocol. Human intravenous immunoglobulin has been used successfully in some horses to temporarily block macrophage receptors and reduce platelet destruction.

Surgical intervention is rarely indicated for ITP itself, though emergency surgery may be necessary to address life-threatening complications such as hemoperitoneum from splenic or hepatic hemorrhage. Splenectomy, which is commonly performed in humans and dogs with refractory ITP to remove the primary site of platelet destruction, is not routinely performed in horses due to surgical risks and the importance of the spleen in equine immune function. Any surgical procedures in horses with active ITP require careful coordination with medical management, ensuring adequate platelet counts before surgery and meticulous hemostasis during the procedure.

Supportive care during ITP treatment includes maintaining the horse in a safe, low-stimulation environment with deep bedding to minimize injury risk. Nutritional support ensures adequate caloric intake and provides nutrients necessary for blood cell production and tissue healing. Gastroprotective medications including omeprazole are administered to prevent gastric ulceration, which is common in stressed horses and could cause additional bleeding in thrombocytopenic patients. Careful monitoring of all bodily functions helps detect early signs of internal hemorrhage requiring intervention. Pain management with appropriate analgesics addresses discomfort from tissue hemorrhages while avoiding medications that might affect platelet function.

Rehabilitation and return to work following ITP treatment proceeds gradually as platelet counts normalize and stabilize. Horses are maintained on tapering immunosuppressive therapy for several weeks to months, with regular blood monitoring to confirm sustained platelet recovery. Physical activity is slowly increased from stall rest to hand walking, then turnout in small paddocks, and finally return to full work over a period of weeks to months depending on individual recovery. Competition horses must observe appropriate withdrawal times for any administered medications, and discussion with regulatory veterinarians may be necessary regarding documentation of treatment for therapeutic use exemptions.

Treatment decision factors influencing management of ITP include the severity of thrombocytopenia and clinical bleeding at presentation, the presence of underlying or concurrent conditions, and the horse's intended use and value. Horses with mild thrombocytopenia and minimal clinical signs may respond to conservative management with lower doses of immunosuppressives, while severe cases require aggressive intervention. The identification of underlying triggers such as infections or drug reactions necessitates addressing these factors alongside immunosuppressive therapy. Financial considerations, potential complications of long-term immunosuppression, and the owner's ability to provide required monitoring and care all influence treatment planning and prognosis discussions.

Recovery timeline for horses with immune-mediated thrombocytopenia varies considerably depending on disease severity, treatment response, and underlying cause. Horses typically begin showing improvement in platelet counts within three to five days of initiating corticosteroid therapy, with many reaching safe levels above 50,000 per microliter within seven to fourteen days. Complete normalization of platelet counts may require several weeks of continued therapy, and some horses demonstrate fluctuating counts during the recovery period. Clinical signs of bleeding typically resolve as platelet counts improve, though resolution of existing hemorrhages into tissues may take additional time as the body reabsorbs extravasated blood. Most uncomplicated primary ITP cases achieve remission within four to eight weeks of treatment initiation.

Post-treatment care involves gradual tapering of immunosuppressive medications over several weeks to months while monitoring for relapse. Abrupt discontinuation of corticosteroids risks both disease recurrence and complications from rapid steroid withdrawal. Regular complete blood counts, initially weekly then biweekly and monthly, track platelet trends throughout the tapering period. Horses are observed closely for any recurrence of bleeding signs, with owners instructed to monitor gum color and check for petechiae daily. Activity levels are gradually increased as clinical status and platelet counts permit, with careful attention to avoiding situations with high injury risk until recovery is well established.

Prognosis factors affecting recovery outcomes include the underlying cause of ITP, severity of initial presentation, and response to treatment within the first week. Primary ITP generally carries a favorable prognosis with appropriate treatment, with approximately seventy to eighty percent of horses achieving sustained remission. Secondary ITP prognosis depends heavily on successful management of the triggering condition, with some causes such as drug reactions resolving completely while others like underlying neoplasia carry guarded prognoses. Horses requiring multiple immunosuppressive agents or experiencing early relapse during treatment tapering may face longer recovery periods and higher risk of chronic disease. Severity of complications including significant anemia or major internal hemorrhage affects both survival and recovery quality.

Long-term soundness outlook for horses recovering from ITP is generally good for those achieving complete and sustained remission. Most horses return to their previous level of performance without lasting limitations from the disease itself, though some may experience prolonged convalescence if significant complications occurred. Horses that develop chronic or relapsing ITP may require long-term low-dose immunosuppressive therapy or repeated treatment courses, potentially limiting competitive careers due to medication withdrawal time requirements. Monitoring for late relapses, which can occur months to years after apparent recovery, should continue throughout the horse's life. Horses that recovered from ITP should be closely observed following any immune-stimulating events such as vaccination or illness.

Prevention of immune-mediated thrombocytopenia focuses on management practices that minimize immune system triggers while maintaining overall horse health. Maintaining horses in consistent, low-stress environments reduces immune system dysregulation that may contribute to autoimmune disease development. Gradual introduction of changes in housing, herd composition, feeding, and exercise routines prevents acute stress responses. Appropriate parasite control, vaccination schedules, and general health maintenance keep horses' immune systems functioning normally without excessive activation. Prompt attention to any illness or injury prevents prolonged immune stimulation that might trigger autoimmune responses in susceptible individuals.

Nutritional management supports healthy immune function through balanced diets providing adequate vitamins, minerals, and essential fatty acids. Antioxidant vitamins including vitamin E and vitamin C support immune cell function and reduce oxidative stress that may contribute to immune dysregulation. Omega-3 fatty acids from sources like flaxseed or fish oil have demonstrated anti-inflammatory effects that may help modulate inappropriate immune responses. Adequate protein intake ensures availability of amino acids necessary for normal immune cell production and function. Avoiding nutritional deficiencies or excesses that might stress the immune system contributes to overall disease prevention.

Exercise and conditioning programs should progress appropriately for each horse's fitness level, avoiding excessive physical stress that might trigger immune abnormalities. Overtraining has been associated with immune suppression followed by rebound hyperactivity in some individuals, potentially creating conditions favorable for autoimmune disease development. Regular moderate exercise supports healthy immune function, while extreme exertion should be followed by adequate recovery periods. Monitoring horses carefully during periods of intensive training allows early detection of any health changes requiring attention.

Environmental factors influencing ITP risk include minimizing exposure to known immune triggers when possible. Careful medication use, with attention to any adverse reactions in individual horses, helps avoid drug-induced ITP. Vaccination protocols should balance disease protection against unnecessary immune stimulation, with veterinary guidance on appropriate timing and frequency of immunizations for individual horses based on their risk factors and history. Biosecurity measures reducing exposure to infectious diseases minimize risk of infection-triggered secondary ITP while protecting overall herd health.

Vaccination and medication considerations for horses at risk of or recovering from ITP require careful veterinary consultation. Modified vaccination protocols may be appropriate for horses with histories of immune-mediated conditions, potentially including extended intervals between vaccinations, avoiding combination vaccines, or selecting specific vaccine products less likely to trigger adverse responses. Pre-vaccination blood work establishing baseline platelet counts allows monitoring for post-vaccination changes. Documentation of all medications administered to horses with ITP histories facilitates identification of potential triggers if relapse occurs. Communication with the veterinary team about the horse's condition ensures appropriate precautions during any necessary treatments or procedures.

Daily management adjustments for horses with ITP or those recovering from the condition focus on minimizing bleeding risk while supporting normal health and quality of life. Stabling arrangements should eliminate sharp edges, protruding objects, and other hazards that could cause cuts or trauma. Feeding and watering setups should allow easy access without competition-related injury risk, and feeders should have smooth surfaces without edges that could cut lips or gums. Turnout companions should be carefully selected to minimize aggressive interactions, with horses prone to kicking or biting excluded from group housing with ITP patients. All routine care activities including grooming, hoof picking, and tacking should be performed gently with attention to avoiding any tissue trauma.

Housing and turnout considerations balance the benefits of exercise and social interaction against injury risk for horses managing ITP. During acute disease or early recovery, strict stall rest provides the safest environment while platelet counts are critically low. As counts improve, gradual introduction of turnout beginning in small, safe enclosures with good footing allows increasing activity. Fencing should be safe and highly visible, with electric fence carefully evaluated as an option since shocks could potentially trigger falling or panicked flight. Footing should be even and free of rocks, holes, or other hazards that could cause stumbling injuries. Shelter from extreme weather prevents stress that might impact immune function.

Exercise modifications during and after ITP depend on current platelet status and overall health. Horses with active disease or very low platelet counts should be restricted to stall rest with hand walking only as permitted by the veterinarian. As platelet counts recover, light exercise may be introduced gradually, beginning with extended hand walking and progressing through light groundwork before any mounted work. High-risk activities including jumping, racing, and intensive training should be delayed until platelet counts are stable and sustained at normal levels. Monitoring for any signs of bleeding or exercise intolerance guides progression decisions, with activity reduction if concerning signs develop.

Monitoring and ongoing care requirements for horses with ITP include regular veterinary evaluations and blood testing as recommended based on disease status. Owners should perform daily observations including checking gums for color and petechiae, examining skin for new hemorrhages, monitoring manure for blood, and assessing overall attitude and appetite. Maintaining detailed records of observations, platelet count results, medication doses, and any clinical events provides valuable information for ongoing management decisions. Establishing relationships with veterinary professionals experienced in immune-mediated diseases ensures appropriate specialist input for complex situations.

Quality of life and use considerations for horses living with or recovered from ITP depend on individual disease behavior and response to treatment. Many horses achieving sustained remission return to full athletic careers without limitations, while others with chronic or relapsing disease may face restrictions based on medication requirements or ongoing bleeding risk. Career planning for competitive horses must account for medication withdrawal times and competition regulations regarding previously treated conditions. Breeding decisions should consider the potential hereditary component of autoimmune diseases, with veterinary genetic counseling appropriate for valuable animals. Ultimately, most horses with successfully treated ITP enjoy good quality of life with appropriate management adaptations.

Immune-mediated thrombocytopenia can affect horses of any breed, with no single breed demonstrating dramatically elevated risk compared to the general population. However, certain breed types may show somewhat higher representation in case reports, potentially reflecting underlying genetic variations in immune regulation. Thoroughbreds and Thoroughbred crosses appear in ITP case series at rates proportional to or slightly higher than their population representation, possibly due to the intensive management and stress exposure common in racing and sport horse careers. Warmbloods and sport horse breeds similarly appear regularly in clinical reports, though whether this reflects true breed susceptibility or simply the close veterinary monitoring these horses receive remains unclear.

Use and discipline considerations affect ITP risk through the stress and immune challenge exposure associated with different equine activities. Performance horses in demanding disciplines experience frequent travel, variable housing conditions, and exposure to horses from multiple populations, creating more opportunities for immune system triggers. Racing Thoroughbreds and competitive sport horses may face higher cumulative stress loads than pleasure horses, potentially increasing autoimmune disease risk over time. However, these same horses receive more intensive veterinary monitoring, potentially leading to earlier detection and diagnosis that could skew apparent breed and use associations. Breeding farms with frequent introduction of new horses face increased infectious disease exposure that could trigger secondary ITP.

Genetic testing specific to ITP is not currently available for horses, unlike some other species where genetic markers for autoimmune disease susceptibility have been identified. Breeding recommendations for horses recovered from ITP should consider the potential hereditary component of immune system regulation, though evidence for direct transmission of ITP susceptibility remains limited. Horses with ITP histories and their close relatives may reasonably be monitored more closely for signs of immune-mediated conditions, and breeding decisions for valuable animals should include veterinary consultation. Maintaining detailed health records across generations helps identify familial patterns that might indicate heritable risk factors requiring consideration in breeding programs.

Immune-mediated thrombocytopenia commonly co-occurs with other autoimmune conditions, reflecting the systemic nature of immune dysregulation underlying these diseases. Immune-mediated hemolytic anemia (IMHA), in which the immune system destroys red blood cells, occurs alongside ITP in a subset of cases, a combination termed Evans syndrome in human medicine. This dual immune attack on blood cells produces both severe anemia and bleeding tendencies, requiring aggressive treatment addressing both components. Systemic lupus erythematosus, though rare in horses compared to dogs and humans, represents another autoimmune condition that may include thrombocytopenia among its manifestations. Horses diagnosed with ITP should be monitored for development of additional immune-mediated conditions.

Conditions with similar symptoms to ITP require differentiation through appropriate diagnostic testing. Warfarin toxicity or ingestion of anticoagulant rodenticides causes bleeding through different mechanisms but may produce similar clinical presentations. Equine viral arteritis and African horse sickness, in regions where it occurs, can cause hemorrhagic manifestations mimicking ITP. Severe liver disease may reduce production of clotting factors, causing bleeding despite normal platelet counts. Disseminated intravascular coagulation produces widespread clotting abnormalities including thrombocytopenia but with characteristic abnormalities in coagulation testing. Vasculitis from various causes produces hemorrhage through blood vessel damage rather than platelet deficiency.

Potential complications of ITP include those arising directly from the platelet deficiency and those related to treatment. Life-threatening hemorrhage into vital organs including the brain, lungs, or gastrointestinal tract represents the most serious direct complication. Secondary anemia from blood loss may become severe enough to require transfusion and carries its own risks including transfusion reactions. Long-term immunosuppressive therapy can predispose horses to secondary infections, may trigger laminitis from corticosteroid administration, and can cause muscle wasting and other metabolic effects. Gastric ulceration occurs commonly in horses with ITP due to stress and corticosteroid treatment, potentially causing additional bleeding complications if ulcers develop before platelet counts recover.